ALLEGRO trial of laquinimod reported in NEJM

Teva/Active Biotech have announced the publication of results from the laquinimod Phase III ALLEGRO study in the March 15 issue of The New England Journal of Medicine. Data from the two-year study showed that oral once-daily laquinimod reduced inflammatory disease activity as measured by clinical relapses and Magnetic Resonance Imaging (MRI), slowed disability progression and decreased brain tissue loss, while maintaining a favorable safety and tolerability profile in patients with relapsing-remitting Multiple Sclerosis. see "Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis"-March 15, 2012 Comi G., Jeffery D., Kappos L., et al. N Engl J Med 2012; 366:1000 - 1009